Welcome to our dedicated page for Alzamend Neuro SEC filings (Ticker: ALZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alzamend Neuro, Inc. files regulatory reports that document its status as a Nasdaq-listed clinical-stage biopharmaceutical company and emerging growth company. Recent disclosures cover common stock registered on The Nasdaq Capital Market, annual meeting and proxy matters, stockholder voting results, and board and governance records.
The company's filings also describe capital-structure activity, including at-the-market offering documents, unregistered common stock issuances tied to convertible preferred stock, elimination of Series B and Series C preferred stock designations, and Nasdaq continued-listing compliance matters. These records frame ALZN's financing, governance and public-company reporting obligations around its neurodegenerative and psychiatric-disorder development programs.
Milton C. Ault III, a director and 10% owner of Alzamend Neuro (ALZN), reported multiple transactions on Form 4. On 07/23/25, his affiliate Ault Lending, LLC converted 332.7553 Series B preferred shares into 143,429 common shares at an effective price of $2.32. The same day it sold 59,516 shares at an average $2.9502; a further 9,621 shares were sold on 07/24/25 at $2.9349.
Following the transactions, Ault Lending holds 82,552 common shares. Including other entities controlled by Mr. Ault (direct 1,843; Ault Life Sciences Inc. 11,068; Ault Life Sciences Fund LLC 61), his aggregate beneficial ownership is ≈95,524 common shares. Derivative positions remain significant: 1,767.2447 Series B preferred shares (no expiration) and 45,569 warrants with strike prices ranging from $108 to $4,050 expiring 2025-2029.
The filing shows a net reduction of roughly 69,137 shares (-42% of the 07/23 conversion) in Ault Lending’s indirect stake. While the conversion eliminates some preferred stock—simplifying the capital structure—the concurrent sales by a large insider can be viewed as a bearish signal for near-term sentiment.
Alzamend Neuro, Inc. (ALZN) has filed an amended Form 144 (Form 144/A) disclosing the intent of an undisclosed shareholder to sell 939,281 shares of common stock through broker E*TRADE Financial on or about 14 July 2025 on the NASDAQ exchange. The filing lists an aggregate market value of US $3,005,699.20 for the proposed sale. For context, the company reports 2,896,432 shares outstanding, meaning the planned disposition represents roughly one-third of the free-trading equity base, a size that can materially influence trading liquidity and share-price dynamics.
The notice also details the historical acquisition of the securities: purchases span private placements, IPO participation, open-market buys, warrant exercises and a sizable 905,172-share commitment tied to Series B convertible preferred stock, plus 25,804 shares available via warrants. Although these convertible and warrant positions are not part of the current sale, their disclosure signals additional potential share supply.
Within the past three months the same party (identified in the filing as Ault Lending, LLC) sold 1,213 shares for gross proceeds of $6,138. No material adverse information is represented, and the seller certifies compliance with Rule 144.
Key takeaways for investors: (1) the block size is large relative to the float, introducing a possible overhang; (2) the transaction is a secondary sale—no new capital accrues to the company; (3) additional convertible and warrant holdings could expand the float further if exercised or converted. The filing is procedural, but the magnitude of the proposed sale makes it noteworthy for liquidity and near-term price action.